Investigational drug · Phase 2
RO7568282
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Parkinson's Disease, Alzheimer's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "RO7568282"
First trial start
2026
Nov 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7568282", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7568282" as an intervention, largest first.
- Study to Test Effects and Safety of RO7568282 in Early Parkinson's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07781644 · 474 participants (planned) · Start Nov 11, 2026 · Primary completion Dec 15, 2028
Drug: RO7568282; Placebo · For: Parkinson's Disease
Sites: Boca Raton, Florida; Shanghai, China; Cork, Ireland · 6 sites in all
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07781657 · 450 participants (planned) · Start Nov 10, 2026 · Primary completion Nov 1, 2029
Drug: RO7568282; Placebo · For: Alzheimer's Disease
Sites: Stuart, Florida; Wellington, Florida; Winter Park, Florida · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Parkinson's Disease
- PrasinezumabRO7046015, PRX002Phase 33 trials
Roche (Genentech) · Parkinson's Disease, Parkinsons Disease
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- GM1Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- BIA 28-6156Phase 21 trial
Bial R&D Investments, S.A. · Parkinson's Disease
- MT101-5Phase 21 trial
Mthera Pharma Co., Ltd. · Parkinson's Disease
- ND0612ND0612HPhase 21 trial
NeuroDerm Ltd. · Parkinson's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.